Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions.

Protein-protein interactions comprise a large class of pharmaceutical targets with significant therapeutic potential. Drugs for such targets are currently dominated by large macromolecular compounds such as the natural receptor, the natural ligand or monoclonal antibodies. These molecules are predominately delivered by injection and are costly to produce.

Many therapeutically-promising targets are considered difficult, if not impossible, to modulate with small molecules. Protagonist Therapeutics has developed a platform capable of designing and synthesizing novel small molecules that modulate such targets, with improved efficacy and delivery characteristics.